Comments
Loading...

Black Diamond Therapeutic

BDTXNASDAQ
Logo brought to you by Benzinga Data
$4.73
-0.09-1.97%
At Close: -
$4.70
-0.03-0.63%
After Hours: 6:17 PM EDT
15 minutes delayed
Consensus Rating1
Outperform
Highest Price Target1
$20.00
Lowest Price Target1
$10.00
Consensus Price Target1
$13.80

Black Diamond Therapeutic (NASDAQ:BDTX) Stock, Analyst Ratings, Price Targets, Forecasts

Black Diamond Therapeutics Inc has a consensus price target of $13.8 based on the ratings of 5 analysts. The high is $20 issued by Raymond James on July 31, 2024. The low is $10 issued by Stifel on June 30, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Wedbush, and HC Wainwright & Co. on September 18, 2024, September 10, 2024, and September 4, 2024, respectively. With an average price target of $12.67 between HC Wainwright & Co., Wedbush, and HC Wainwright & Co., there's an implied 169.50% upside for Black Diamond Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Jun
2
Jul
1
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Wedbush
Raymond James
Piper Sandler
Stifel

1calculated from analyst ratings

Analyst Ratings for Black Diamond Therapeutic

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Black Diamond Therapeutic (BDTX) stock?

A

The latest price target for Black Diamond Therapeutic (NASDAQ:BDTX) was reported by HC Wainwright & Co. on September 18, 2024. The analyst firm set a price target for $11.00 expecting BDTX to rise to within 12 months (a possible 134.04% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?

A

The latest analyst rating for Black Diamond Therapeutic (NASDAQ:BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic reiterated their buy rating.

Q

When was the last upgrade for Black Diamond Therapeutic (BDTX)?

A

The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.

Q

When was the last downgrade for Black Diamond Therapeutic (BDTX)?

A

The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

Q

Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?

A

While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $11.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $4.70, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch